

# Cancer patients admitted to intensive care unit

Uchiyama M.<sup>1</sup>, Maezawa Y.<sup>2</sup>, Satoh H.<sup>2</sup>, Hasegawa R.<sup>1</sup>

<sup>1</sup>Department of Intensive Care Medicine, Dokkyo Medical University, Saitama Medical Center, Koshigaya, Japan

<sup>2</sup>Division of Internal Medicine, Mito Medical Center, University of Tsukuba-Mito, Kyodo General Hospital, Mito, Japan

Dear Editor,

We read with interest the article by Kraft Rovere et al. published in the October 2025 issue of *Klinická onkologie* on cancer patients admitted to intensive care unit – a six-year retrospective analysis [1]. We agree with you that it is difficult to determine whether a seriously ill cancer patient should be admitted to the ICU. When deciding whether to admit cancer patients to the ICU for intensive therapy, it is necessary to consider not only whether their life can be saved, but also whether cancer treatment can be continued after ICU treatment. We would appreciate if you could let us know about this point in the cancer patients examined in this study. In particular, as you pointed out, how has the aging population affected ICU therapy for cancer patients? Have there been any changes over time? Please let us know about these points. As the au-

thors described at the end of the discussion, we do agree with your opinion that evaluation of the anti-cancer treatment being administered, the response to treatment, the patient's prognosis considering the cancer, and the reversibility of the acute illness are important for admission of IUC therapy in cancer patients. Future studies investigating these items will likely be published. Such information will be important for evaluating the quality of medical care at facilities and for maintaining that quality in the future. We would appreciate if you could build on your results and tell us how else these important findings can be used.

## Reference

1. Kraft Rovere R, Pires de Souza ME, Rodrigues Chamse Ddine Y et al. Cancer patients admitted to intensive care unit – a six-year retrospective analysis. *Klin Onkol* 2025; 38(5): 381–385. doi: 10.48095/ccko2025381.

The authors declare that they have no potential conflicts of interest concerning drugs, products, or services used in the study.

Autoři deklarují, že v souvislosti s předmětem studie nemají žádné komerční zájmy.

The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.

Redakční rada potvrzuje, že rukopis práce splnil ICMJE kritéria pro publikace zasílané do biomedicínských časopisů.



**Hiroaki Satoh, MD, PhD**

Division of Respiratory Medicine

Mito Medical Center

University of Tsukuba-Mito Kyodo

General Hospital

3-2-7 Miya-machi, Mito

Ibaraki, 310-0015

e-mail: 0809hirosato@gmail.com

Submitted: 25. 1. 2026

Accepted: 28. 1. 2026

doi: 10.48095/ccko2026126